Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -10.26% | 1,083.33% |
| Total Other Revenue | 190.49% | 190.49% | 190.49% | 283.33% | -- |
| Total Revenue | 190.49% | 190.49% | 190.49% | 253.85% | 1,083.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 190.49% | 190.49% | 190.49% | 253.85% | 1,083.33% |
| SG&A Expenses | -67.99% | 9.65% | 387.49% | 854.78% | 87,175.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.40% | -18.06% | 15.87% | 5.96% | -1.77% |
| Operating Income | 53.07% | 23.50% | -10.89% | -2.51% | 3.87% |
| Income Before Tax | 42.55% | 22.85% | 3.22% | 10.79% | 16.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.55% | 22.85% | 3.22% | 10.07% | 15.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.55% | 22.85% | 3.22% | 10.07% | 15.21% |
| EBIT | 53.07% | 23.50% | -10.89% | -2.51% | 3.87% |
| EBITDA | 76.20% | 36.34% | -10.91% | -2.52% | 3.80% |
| EPS Basic | 60.00% | 40.00% | 20.00% | 25.00% | 28.57% |
| Normalized Basic EPS | 33.33% | 16.67% | 0.00% | 25.00% | 40.00% |
| EPS Diluted | 60.00% | 40.00% | 20.00% | 25.00% | 28.57% |
| Normalized Diluted EPS | 33.33% | 16.67% | 0.00% | 25.00% | 40.00% |
| Average Basic Shares Outstanding | 10.68% | 16.68% | 23.47% | 26.07% | 29.03% |
| Average Diluted Shares Outstanding | 10.68% | 16.68% | 23.47% | 26.07% | 29.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |